On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Imagenetix, Inc. (IAGX) Addressing Underserved Medical Needs through Development and Commercialization of Bioceutical Products

Imagenetix, Inc. (OTC: IAGX) is an innovator of natural bioceutical products designed to enhance human health on a global basis. By concentrating on human and animal conditions related to inflammation and obesity, the company has achieved significant advancements in the successful research, development and commercialization of safe compositions to reduce body fat and enhance overall body composition. In particular, Imagenetix develops and formulates proprietary over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution.

In addition to these products, Imagenetix is currently undertaking research and development initiatives based on a cascade of inflammatory events shown to be correlative to a number of diseases. The company’s first therapeutic drug, 1-TDC, was developed for the treatment and prevention of periodontal disease, and, according to studies by Boston University, the drug is effective in halting the progression of gum and bone damage.

Data from the Centers for Disease Control and Prevention shows the massive market potential for 1-TDC moving forward. According to the report, approximately 50 percent of all American adults aged 30 or over suffers from periodontal disease. In adults 65 or older, prevalence rates rise dramatically to approximately 70 percent of individuals.

“We are excited with… the potential of our compound to become a major breakthrough for the prevention of periodontal disease,” William P. Spencer, president of Imagenetix, stated in a news release. The prevalence of the disease among Americans “creates a potential multi-billion [dollar] market for a product developed from our compound.”

In recent years, the company’s primary product has been Celadrin. This medically and clinically proven pain management compound has been shown to dramatically reduce inflammation and pain, providing Imagenetix with access to another market with near limitless potential for growth in the future.

Through a balance of research and development initiatives and continued marketing of its existing product offerings, Imagenetix could be in a strong position to realize increased market share in the years to come. For prospective shareholders, the company’s established presence within the over-the-counter pharmaceutical industry makes it an interesting investment opportunity moving forward.

For more information, visit www.imagenetix.com

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.